|Mr. Richard C. Williams||Independent Chairman & Consultant||128k||N/A||1944|
|Dr. Dennis J. Carlo||Pres, CEO & Director||982.81k||N/A||1943|
|Mr. Robert O. Hopkins||Sr. VP of Fin., CFO & Sec.||579.96k||N/A||1960|
|Mr. David J. Marguglio||Sr. VP, Chief Bus. Officer & Director||N/A||N/A||1970|
|Dr. Ronald B. Moss||Chief Medical Officer||613.65k||N/A||1961|
|Mr. Howard C. Birndorf||Independent Director & Consultant||64k||N/A||1951|
|Ms. Roshawn A. Blunt||Independent Director & Consultant||64k||N/A||1975|
|Ms. Karen K. Daniels||VP of Operations||N/A||N/A||1953|
|Mr. David C. Benedicto||Principal Accounting Officer||N/A||N/A||1961|
|Mr. Mark Flather||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Adamis Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.